Artelo Biosciences ARTL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.01 (-0.99%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Artelo Biosciences (ARTL)
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1

  • Market Cap

    $3.28 Million

  • Total Outstanding Shares

    3.28 Million Shares

  • Total Employees

    6

  • Dividend

    No dividend

  • IPO Date

    October 13, 2015

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    505 lomas santa fe, suite 160, Solana beach, CA, 92075

  • Homepage

    https://www.artelobio.com

Historical Stock Splits

If you bought 120 shares of ARTL before June 21, 2019, you'd have 1 share today.
Execution DateSplit Amount
August 10, 20221-for-15 (Reverse Split)
June 21, 20191-for-8 (Reverse Split)

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Investing Activities$7.77 Million
Net Cash Flow, Continuing$-469,000
Net Cash Flow From Operating Activities$-8.35 Million
Net Cash Flow From Financing Activities$112,000
Exchange Gains/Losses$-8,000
Net Cash Flow$-477,000

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-9.83 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Preferred Stock Dividends And Other Adjustments$0
Diluted Earnings Per Share$-3.05
Income Tax Expense/Benefit$0
Nonoperating Income/Loss$282,000

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$-9.82 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$1,000
Comprehensive Income/Loss Attributable To Parent$-9.82 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Other Non-current Assets$102,000
Current Liabilities$1.77 Million
Liabilities And Equity$4.70 Million
Current Assets$2.56 Million
Liabilities$1.84 Million
Equity Attributable To Parent$2.86 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ARTL from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.